http://www.reportsnreports.com/CHI Healthtech Market Research Reports XML feedhttp://www.reportsnreports.com/reports/164277-the-new-generation-of-antibody-therapeutics-current-status-and-future-prospects.htmlAntibody sales are predicted to reach $50 billion this year. This Insight Pharma Report focuses on recent developments in the therapeutic antibody field and new technologies built on the foundations of previously successful and unsuccessful strategies. Following a review of the business environment and market forces, this report examines: &nbsp;The state of the art, and the needs and direction, of antibody technology todayAntibody conjugates and other payloads: construction, clinical development, and corporate activityMultispecific and multifunctional antibodies: construction, clinical development, and corporate activityDevelopment of biosimilars and b...Wed, 06 Jun 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/157192-backup-compound-strategies-commercial-and-tactical-considerations.htmlOnly about 20% of compounds that advance to clinical trials reach the market. Given this high rate of attrition and ever-increasing costs, companies need fallback plans as an alternative to canceling projects and writing off significant investments. Planning optimal backup compound strategies is often difficult. This Insight Pharma Report: &nbsp;Describes how companies are addressing strategic and tactical issues concerning backup compounds and predicts how they are likely to do so in the futureProvides perspective on best practices to adopt in addressing relevant backup compound issues and how evolution in de-risking technologies may affect those practicesPresents ca...Mon, 23 Apr 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/148925-hematological-cancer-therapies-pipelines-markets-and-business-considerations.htmlIn recent years, newer and more specific therapies for hematological cancers have been developed, such as targeted small-molecule drugs and biological therapies including monoclonal antibodies. However, there remains significant need from a clinical perspective, as well as challenges and opportunities for pharmaceutical companies. This report discusses:The different types of hematological cancers, including information about the specific disease, its epidemiology, subtypes and/or staging if appropriate, current therapies, and patient prognosis.Pipelines of emerging drugs for treatment of hematological cancers including leukemia, lymphoma, myeloma, myelodysplastic syndromes, an...Thu, 23 Feb 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/166238-the-pi3k-akt-mtor-pathway-a-pipeline-analysis.htmlThe PI3K/Akt/mTOR signaling cascade serves many physiological and pathophysiological functions and is of major importance in a broad array of cancers. This has stimulated substantial interest in identifying and developing modulators of this pathway. This report includesPipeline reviews of PI3K, Akt, mTOR, and dual kinase inhibitors in development and an assessment of the current prospects for each approachRole of the PI3K/Akt/mTOR cascade in various diseases and potential intervention strategiesSurvey results offering unique insights into industry sentiment concerning development of inhibitors of this pathwayProfiles of selected compan...Wed, 30 Nov 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/150304-cytokine-based-therapies-and-inhibitors-rd-pipelines-markets-and-strategic-issues-overview.htmlEmerging cytokine-based therapies, and inhibitors of cytokines and their receptors, represent attractive markets that have become highly competitive. More than 120 companies are developing over 270 new therapies that either are cytokines, mimic cytokines, or inhibit cytokines and/or cytokine receptors. This report examines:Marketed cytokine-based therapies and inhibitors, and emerging new therapiesActivities to expand approved indications for cytokines and cytokine inhibitorsPipeline of cytokine therapies and inhibitors in development, their targeted indications, clinical progress/data, issues or hurdlesCurrent and potential markets for cytokines and cytokine...Fri, 30 Sep 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/89350-multitargeted-therapies-promiscuous-drugs-and-combination-therap.htmlSuites of drugs have been developed that can be used in combination to treat complex diseases that have multiple causes involving multiple targets. In addition, it has been found that many successful small-molecule drugs are promiscuous, i.e., they are single drugs that address multiple targets. This report covers both these major approaches to development of multitargeted therapies. Discussed are:The discovery and design of promiscuous drugsThe rational design of novel combination therapies designed to address multiple...Wed, 22 Jun 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/88949-direct-to-consumer-genetic-testing-business-prospects-in-the-uni.htmlDirect-To-Consumer Genetic Testing: Business Prospects in the United States covers the business of genetic tests marketed and sold directly to consumers (DTC), with special attention paid to the small, emerging, and definitely attention-getting segment called Personal Genomics. Thanks to the confluence of two transformational technologies that derive from the invention of the Internet and the completion of the Human Genome Project, the availability of genetic tests is migrating from the scientist- and health professional-controlled domains of research (hospital and clinical laboratories) to the wi...Fri, 10 Jun 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/21670-animal-models-for-therapeutic-strategies.htmlModel organisms have long been a mainstay of basic and applied research in the life sciences. Among model organisms, it is model animals that have had a central place in medical research and in pharmaceutical and biotechnology company research, including drug discovery, preclinical studies, and toxicology. Although pharmaceutical companies have long employed animal models based on such mammalian species as mice and rats, dogs, cats, pigs, and primates, more recently the pharmaceutical/biotechnology industry has also adopted several invertebrate and lower vertebrate animal models that have emerged from a...Fri, 10 Jun 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/21664-outsourcing-preclinical-studies-to-china-benefits-and-challenges.htmlWithin the past several years in China, a number of state-owned labs as well as private and joint venture CRO&rsquo;s have or will soon offer preclinical GLP study services to Western clients. This report, built on discussions, facility visits, and in many cases study monitoring and/or auditing at the most advanced labs, provides a detailed view of the current and evolving preclinical study capabilities in China, their structures and services as well as an analysis of the comparative costs between US and China-based CRO&rsquo;s.This report reviews the state of p...Fri, 10 Jun 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/88950-strategic-management-of-resources-and-portfolios.htmlAs a company develops its business, resources will always be limited and risk will always be involved. This is especially true for companies operating in the high-risk life science industry. To stay on top of the changing pharmaceutical R&amp;D environment, certain measures must be implemented. This report analyzes:Types of risk that must be faced;Ways that various risks can be assessed and managed;How corporate resources can be allocated to meet the goals and create maximum value a...Fri, 10 Jun 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/80520-commercializing-biomarkers-in-therapeutic-and-diagnostic-applicat.htmlBiomarkers feature in thousands of published articles each year, evidencing the high level of interest and research in this field. This report focuses on issues that must be addressed to utilize this growing knowledge about biomarkers and successfully commercialize them in therapeutic and diagnostic applications. Included in this publication:&nbsp;&nbsp;Biomarker definitions and guidelines for their development and validationApplications of biomarkers in oncology, cardiology, neurology, drug safety, and other areas...Thu, 12 May 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/80521-monoclonal-antibodies-in-the-pipeline-a-segment-of-major-growth-.htmlMonoclonal antibodies are highly valuable therapeutic agents and were among the best-selling drugs in the world in 2010. Global revenues from monoclonal antibody products will have moved significantly past the $40 billion level in 2010 and are poised to continue growing steadily through to 2015.Nearly 300 monoclonal antibodies currently in clinical development, organized by indication and/or targetSales of currently marketed monoclonal antibodies, market share by compan...Mon, 28 Mar 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/80522-molecular-diagnostics-double-digit-growth-anticipated-report.htmlIndustry-leading growth rates, expanding applications and innovation characterize the molecular diagnostics sector. This report presents a synthesis of these developments including the increased diversity of assay targets, emergence of new and proposed point of care (POC) products, the appearance of sequencing-based assays that could fundamentally alter the field and automated low-density microarray-based assays.&nbsp;Discussed in this report:The technological landscape underlying molecular diagnostics to...Sat, 05 Feb 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/21673-strategic-alliances-synergistic-path-to-value-creation.htmlExecutive Leading up to 2009, a confluence of events created substantial challenges for the pharmaceutical industry. Global pharmaceutical drug candidate submission and approval rates have fallen during the past 5 years while the aggregate of R&amp;D expenditures have risen in an attempt to spur the creation of replacement products. Added to this, Wall Street analysts forecast Big Pharma to lose $140 billion in annual sales by 2016 as patents for premier products, includ...Tue, 11 Jan 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/80523-advanced-drug-delivery-technologies-enabling-drug-reformulations.htmlExciting developments are occurring in the field of alternative drug delivery&mdash;a phrase that describes the reformulation of drugs to enable lower doses, more convenient delivery routes, and supplemental therapeutic indications. This report presents an overview of these developments, describes the options that new formulation technologies are creating, and explores the medical and commercial perspectives.Discussed in this report:The enabling role of med...Sat, 01 Jan 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/34198-diabetes-pipeline-intense-activity-to-meet-unmet-need-report.htmlDiabetes has serious consequences if it is not well treated. In 2010, the global prevalence of diabetes was estimated to have reached 285 million and it is predicted to reach 438 million in 2030. Available agents provide imperfect control of the disease, and the medical need for better therapies is widely recognized. This report discusses:Pros and cons of marketed therapies and snapshots of the global diabetes marketDevelopment pipelines and approaches that are being takenAnticipated FDA filing dates for significant new productsProfiles of selected companies that are active in the field, including major and emerging...Wed, 01 Sep 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/34200-therapeutic-protein-production-a-changing-landscape.htmlTherapeutic Protein Production: A Changing Landscape examines the implications of and advances in upstream and downstream operations used in the production of therapeutic proteins. Improvements in protein yields per unit volume, the significance of introducing disposables throughout the process and the shift to animal extracts-free culture media are three of the major themes covered by this report. The impact of global competition, lower barriers to entry and the shift in the production bottleneck from upstream to downstream unit operations are presented together with likely shifts impacting the production outlook over the next five years. More than a do...Thu, 01 Jul 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/34201-drug-repositioning.htmlDrug repositioning has become a matter of intense interest during the past few years. It is an approach to drug development that calls for reinvestigation of candidates that did not succeed in advanced clinical trials (for reasons other than safety) for potential use in other therapeutic indications.Discussed in this Report: Intellectual property coverage for new uses of known drugsTool sets for identifying repositioning opportunities and business strategiesApplicable legal frameworks and regulatory timelines for repositioned drugsCase studies of compound repositioning and approaches taken</l...Thu, 01 Jul 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/34199-therapeutic-monoclonal-antibody-production.htmlBioprocessing is the branch of biotechnology dealing with the production and purification of biological materials of commercial interest. This report focuses on the wide ranging disciplines applied to the goal of rapidly, accurately and economically complex monoclonal antibody molecules. While most antibody biologics are anti-cancer agents, there are a number of other areas of disease management to which biologics in this class are starting to play a significant role. These indications include immune dysfunction, infectious disease and mental illness.Trends in the upstream and the downstream areas of monoclonal antibody production are encouraging,...Thu, 01 Jul 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/34202-epigenetic-drug-diagnostic-pipelines-dna-methylation-hdac-inh.htmlEpigenetics is a rapidly growing field with promising implications for treatment of cancer and potentially other diseases. Research interest in epigenetics has exploded in recent years, and considerable progress has been made in the commercialization of discoveries in this field. Discussed in this Report: Diagnostic applications of epigeneticsDiseases and conditions targeted by current and emerging epigenetic-based therapiesCompanies marketing and/or developing therapies that target epigenetic changes within the disease processCurrent and projected markets for epigenetic diagnostic and t...Tue, 01 Jun 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/34203-epigenetic-drug-diagnostic-pipelines.htmlEpigenetics is a rapidly growing field with promising implications for treatment of cancer and potentially other diseases. Research interest in epigenetics has exploded in recent years, and considerable progress has been made in the commercialization of discoveries in this field.Discussed in this Report: Diagnostic applications of epigeneticsDiseases and conditions targeted by current and emerging epigenetic-based therapiesCompanies marketing and/or developing therapies that target epigenetic changes within the disease processCurrent and projected markets for epigenetic diagnostic and therapeutic produ...Sat, 01 May 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/34204-combination-drug-diagnostic-products-and-other-applications-of-pe.htmlThe focus of this report is on drug/diagnostic combinations -- drugs used to treat patients, and on diagnostic tests that can provide information about how a patient may respond to treatment with that drug.Personalized medicine has emerged as an important field for companies in both the pharmaceutical and the diagnostic industries. While many drugs in development and on the market today still follow the traditional approach where drugs are developed to treat all patients with a certain disease or condition, the one-size fits all approach, it is now widely recognized that not all drugs work equally well in all patients. Also, some perce...Thu, 01 Apr 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/21665-cloud-computing-in-life-sciences-rd.htmlThe pharmaceutical outsourcing trend and economic restrictions, coupled with the increasing attractiveness of cloud computing offerings, have created a highly dynamic yet nascent market. Included in this report:Technological aspects of cloud computing and activities of companies that are active in the fieldCurrent and emerging applications of cloud computing, with special emphasis on next-generation sequencing and its resultant dataMarket aspects of cloud computing, including competition among providers and user requirementsResults and analysis from an extensive survey of bioinformatics people concerning their practices and viewsExpert interviews</li...Thu, 01 Apr 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/21661-combination-drug-diagnostics-fueling-growth-of-personalized-medi.htmlReport Description:The focus of this report is on drug/diagnostic combinations -- drugs used to treat patients, and ondiagnostic tests that can provide information about how a patient may respond to treatment with that drug.Personalized medicine has emerged as an important field for companies in both the pharmaceutical and diagnostic industries. While many drugs in development and on the market today still follow the traditional approach where drugs are developed to treat all patients with a certain disease or condition, the one-size fits all&rdquo; approach, it is now widely recognized that not all drugs work equally well in all patients. Also, some percentage...Thu, 01 Apr 2010 00:00:00 GMThttp://www.reportsnreports.com/reports/21663-multiplex-assays-evolving-technologies-applications-and-future-.htmlReport Description:Multiplex Assays: Evolving Technologies, Applications and Future Directions focuses on significant recent developments in the multiplex assay field. Pharmaceutical companies are increasingly committing to associating their drugs with diagnostic assays. The majority of these are single-analyte biomarkers. However, a number of multiplex biomarkers not directly associated with particular drugs are in use as approved or homebrew diagnostics, and these contribute in various ways to the broad field of translational medicine. This report examines the role of multiplex and multi-analyte biomarker assays in translational medicine and their direct contributions to ...Fri, 01 Jan 2010 00:00:00 GMT